LB Pharmaceuticals names Joseph Miller as chief financial officer
The neuromedicines company said Miller starts as CFO effective September 2, 2026, ahead of pivotal NOVA-2 trial results for LB-102 in schizophrenia.
SEC filing
Latest
2 stories
Thursday, September 3
Thursday, August 6
Avalo reports Q2 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027
Avalo also detailed a new anti-IL-1β antibody, AVTX-010, with an IND filing targeted for the first half of 2027, and reported $472.2 million in cash.
SEC filing